AVANT to Present at Harris Nesbitt Focus on Healthcare Conference.NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Avery (Chip) W. Catlin, Senior Vice President and Chief Financial Officer of AVANT Immunotherapeutics, Inc., will present at the Harris Nesbitt Focus on Healthcare Conference at the Metropolitan Club, 1 East 60th Street in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on Wednesday, December 8th at 2:45 pm, EST EST electroshock therapy. EST abbr. electroshock therapy . A live webcast of the presentation will be available online via the Investor Information area of AVANT's website at http://www.avantimmune.com. An archive of the webcast will be available via AVANT's website for approximately 90 days following the event. AVANT Immunotherapeutics, Inc. discovers, develops and sells innovative vaccines and therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. The company has developed a broad, well- staged pipeline of vaccines and therapeutics for large, high-value, under-served markets. Six of AVANT's products are in clinical development. These include an oral human rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccine which gained its first marketing approval in Mexico in July 2004, a treatment to reduce complement-mediated tissue damage associated with cardiac by-pass surgery, and a novel vaccine for cholesterol management. AVANT has also assembled a technology platform that enables the creation of rapid-protecting, single-dose, oral vaccines that remain stable without refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. . The company is developing applications of this vaccine technology in four areas: biodefense, travelers' vaccines, global health needs, and human food safety. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging further development through both traditional pharmaceutical partnerships and collaborations with governmental and other organizations. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion